Global Oligonucleotide Drugs (ONs) Market Research Report 2024(Status and Outlook)
![](/report_cover/11711/global-oligonucleotide-drugs-ons-market-research-report-2024status-n-outlook_en.gif)
Report Overview
Nucleic acid medicines utilize nucleic acid, which refer to substances such as DNA and RNA that control genetic information, as drugs. These allow targeting of molecules such as mRNA and miRNA that cannot be targeted with traditional low molecular weight drugs and antibody medicines, and there is a great expectation for these drugs as next generation pharmaceuticals. Active research is being conducted globally as it is expected to lead to the creation of drugs which were previously intractable.
This report provides a deep insight into the global Oligonucleotide Drugs (ONs) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Oligonucleotide Drugs (ONs) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Oligonucleotide Drugs (ONs) market in any manner.
Global Oligonucleotide Drugs (ONs) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Novartis
Ionis
Nippon Shinyaku
Alnylam
Sarepta Therapeutics
MiNA Therapeutics
BioNTech
Moderna
Market Segmentation (by Type)
ASO
siRNA
Other
Market Segmentation (by Application)
Cardiovascular Diseases
Hepatitis B
Hypertension
Other
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Oligonucleotide Drugs (ONs) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Nucleic acid medicines utilize nucleic acid, which refer to substances such as DNA and RNA that control genetic information, as drugs. These allow targeting of molecules such as mRNA and miRNA that cannot be targeted with traditional low molecular weight drugs and antibody medicines, and there is a great expectation for these drugs as next generation pharmaceuticals. Active research is being conducted globally as it is expected to lead to the creation of drugs which were previously intractable.
This report provides a deep insight into the global Oligonucleotide Drugs (ONs) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Oligonucleotide Drugs (ONs) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Oligonucleotide Drugs (ONs) market in any manner.
Global Oligonucleotide Drugs (ONs) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Novartis
Ionis
Nippon Shinyaku
Alnylam
Sarepta Therapeutics
MiNA Therapeutics
BioNTech
Moderna
Market Segmentation (by Type)
ASO
siRNA
Other
Market Segmentation (by Application)
Cardiovascular Diseases
Hepatitis B
Hypertension
Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Oligonucleotide Drugs (ONs) Market
- Overview of the regional outlook of the Oligonucleotide Drugs (ONs) Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Oligonucleotide Drugs (ONs) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Oligonucleotide Drugs (ONs)
1.2 Key Market Segments
1.2.1 Oligonucleotide Drugs (ONs) Segment by Type
1.2.2 Oligonucleotide Drugs (ONs) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 OLIGONUCLEOTIDE DRUGS (ONS) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Oligonucleotide Drugs (ONs) Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Oligonucleotide Drugs (ONs) Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 OLIGONUCLEOTIDE DRUGS (ONS) MARKET COMPETITIVE LANDSCAPE
3.1 Global Oligonucleotide Drugs (ONs) Sales by Manufacturers (2019-2024)
3.2 Global Oligonucleotide Drugs (ONs) Revenue Market Share by Manufacturers (2019-2024)
3.3 Oligonucleotide Drugs (ONs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Oligonucleotide Drugs (ONs) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Oligonucleotide Drugs (ONs) Sales Sites, Area Served, Product Type
3.6 Oligonucleotide Drugs (ONs) Market Competitive Situation and Trends
3.6.1 Oligonucleotide Drugs (ONs) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Oligonucleotide Drugs (ONs) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 OLIGONUCLEOTIDE DRUGS (ONS) INDUSTRY CHAIN ANALYSIS
4.1 Oligonucleotide Drugs (ONs) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF OLIGONUCLEOTIDE DRUGS (ONS) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 OLIGONUCLEOTIDE DRUGS (ONS) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Oligonucleotide Drugs (ONs) Sales Market Share by Type (2019-2024)
6.3 Global Oligonucleotide Drugs (ONs) Market Size Market Share by Type (2019-2024)
6.4 Global Oligonucleotide Drugs (ONs) Price by Type (2019-2024)
7 OLIGONUCLEOTIDE DRUGS (ONS) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Oligonucleotide Drugs (ONs) Market Sales by Application (2019-2024)
7.3 Global Oligonucleotide Drugs (ONs) Market Size (M USD) by Application (2019-2024)
7.4 Global Oligonucleotide Drugs (ONs) Sales Growth Rate by Application (2019-2024)
8 OLIGONUCLEOTIDE DRUGS (ONS) MARKET SEGMENTATION BY REGION
8.1 Global Oligonucleotide Drugs (ONs) Sales by Region
8.1.1 Global Oligonucleotide Drugs (ONs) Sales by Region
8.1.2 Global Oligonucleotide Drugs (ONs) Sales Market Share by Region
8.2 North America
8.2.1 North America Oligonucleotide Drugs (ONs) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Oligonucleotide Drugs (ONs) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Oligonucleotide Drugs (ONs) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Oligonucleotide Drugs (ONs) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Oligonucleotide Drugs (ONs) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Novartis
9.1.1 Novartis Oligonucleotide Drugs (ONs) Basic Information
9.1.2 Novartis Oligonucleotide Drugs (ONs) Product Overview
9.1.3 Novartis Oligonucleotide Drugs (ONs) Product Market Performance
9.1.4 Novartis Business Overview
9.1.5 Novartis Oligonucleotide Drugs (ONs) SWOT Analysis
9.1.6 Novartis Recent Developments
9.2 Ionis
9.2.1 Ionis Oligonucleotide Drugs (ONs) Basic Information
9.2.2 Ionis Oligonucleotide Drugs (ONs) Product Overview
9.2.3 Ionis Oligonucleotide Drugs (ONs) Product Market Performance
9.2.4 Ionis Business Overview
9.2.5 Ionis Oligonucleotide Drugs (ONs) SWOT Analysis
9.2.6 Ionis Recent Developments
9.3 Nippon Shinyaku
9.3.1 Nippon Shinyaku Oligonucleotide Drugs (ONs) Basic Information
9.3.2 Nippon Shinyaku Oligonucleotide Drugs (ONs) Product Overview
9.3.3 Nippon Shinyaku Oligonucleotide Drugs (ONs) Product Market Performance
9.3.4 Nippon Shinyaku Oligonucleotide Drugs (ONs) SWOT Analysis
9.3.5 Nippon Shinyaku Business Overview
9.3.6 Nippon Shinyaku Recent Developments
9.4 Alnylam
9.4.1 Alnylam Oligonucleotide Drugs (ONs) Basic Information
9.4.2 Alnylam Oligonucleotide Drugs (ONs) Product Overview
9.4.3 Alnylam Oligonucleotide Drugs (ONs) Product Market Performance
9.4.4 Alnylam Business Overview
9.4.5 Alnylam Recent Developments
9.5 Sarepta Therapeutics
9.5.1 Sarepta Therapeutics Oligonucleotide Drugs (ONs) Basic Information
9.5.2 Sarepta Therapeutics Oligonucleotide Drugs (ONs) Product Overview
9.5.3 Sarepta Therapeutics Oligonucleotide Drugs (ONs) Product Market Performance
9.5.4 Sarepta Therapeutics Business Overview
9.5.5 Sarepta Therapeutics Recent Developments
9.6 MiNA Therapeutics
9.6.1 MiNA Therapeutics Oligonucleotide Drugs (ONs) Basic Information
9.6.2 MiNA Therapeutics Oligonucleotide Drugs (ONs) Product Overview
9.6.3 MiNA Therapeutics Oligonucleotide Drugs (ONs) Product Market Performance
9.6.4 MiNA Therapeutics Business Overview
9.6.5 MiNA Therapeutics Recent Developments
9.7 BioNTech
9.7.1 BioNTech Oligonucleotide Drugs (ONs) Basic Information
9.7.2 BioNTech Oligonucleotide Drugs (ONs) Product Overview
9.7.3 BioNTech Oligonucleotide Drugs (ONs) Product Market Performance
9.7.4 BioNTech Business Overview
9.7.5 BioNTech Recent Developments
9.8 Moderna
9.8.1 Moderna Oligonucleotide Drugs (ONs) Basic Information
9.8.2 Moderna Oligonucleotide Drugs (ONs) Product Overview
9.8.3 Moderna Oligonucleotide Drugs (ONs) Product Market Performance
9.8.4 Moderna Business Overview
9.8.5 Moderna Recent Developments
10 OLIGONUCLEOTIDE DRUGS (ONS) MARKET FORECAST BY REGION
10.1 Global Oligonucleotide Drugs (ONs) Market Size Forecast
10.2 Global Oligonucleotide Drugs (ONs) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Oligonucleotide Drugs (ONs) Market Size Forecast by Country
10.2.3 Asia Pacific Oligonucleotide Drugs (ONs) Market Size Forecast by Region
10.2.4 South America Oligonucleotide Drugs (ONs) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Oligonucleotide Drugs (ONs) by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Oligonucleotide Drugs (ONs) Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Oligonucleotide Drugs (ONs) by Type (2025-2030)
11.1.2 Global Oligonucleotide Drugs (ONs) Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Oligonucleotide Drugs (ONs) by Type (2025-2030)
11.2 Global Oligonucleotide Drugs (ONs) Market Forecast by Application (2025-2030)
11.2.1 Global Oligonucleotide Drugs (ONs) Sales (Kilotons) Forecast by Application
11.2.2 Global Oligonucleotide Drugs (ONs) Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Oligonucleotide Drugs (ONs)
1.2 Key Market Segments
1.2.1 Oligonucleotide Drugs (ONs) Segment by Type
1.2.2 Oligonucleotide Drugs (ONs) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 OLIGONUCLEOTIDE DRUGS (ONS) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Oligonucleotide Drugs (ONs) Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Oligonucleotide Drugs (ONs) Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 OLIGONUCLEOTIDE DRUGS (ONS) MARKET COMPETITIVE LANDSCAPE
3.1 Global Oligonucleotide Drugs (ONs) Sales by Manufacturers (2019-2024)
3.2 Global Oligonucleotide Drugs (ONs) Revenue Market Share by Manufacturers (2019-2024)
3.3 Oligonucleotide Drugs (ONs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Oligonucleotide Drugs (ONs) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Oligonucleotide Drugs (ONs) Sales Sites, Area Served, Product Type
3.6 Oligonucleotide Drugs (ONs) Market Competitive Situation and Trends
3.6.1 Oligonucleotide Drugs (ONs) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Oligonucleotide Drugs (ONs) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 OLIGONUCLEOTIDE DRUGS (ONS) INDUSTRY CHAIN ANALYSIS
4.1 Oligonucleotide Drugs (ONs) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF OLIGONUCLEOTIDE DRUGS (ONS) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 OLIGONUCLEOTIDE DRUGS (ONS) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Oligonucleotide Drugs (ONs) Sales Market Share by Type (2019-2024)
6.3 Global Oligonucleotide Drugs (ONs) Market Size Market Share by Type (2019-2024)
6.4 Global Oligonucleotide Drugs (ONs) Price by Type (2019-2024)
7 OLIGONUCLEOTIDE DRUGS (ONS) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Oligonucleotide Drugs (ONs) Market Sales by Application (2019-2024)
7.3 Global Oligonucleotide Drugs (ONs) Market Size (M USD) by Application (2019-2024)
7.4 Global Oligonucleotide Drugs (ONs) Sales Growth Rate by Application (2019-2024)
8 OLIGONUCLEOTIDE DRUGS (ONS) MARKET SEGMENTATION BY REGION
8.1 Global Oligonucleotide Drugs (ONs) Sales by Region
8.1.1 Global Oligonucleotide Drugs (ONs) Sales by Region
8.1.2 Global Oligonucleotide Drugs (ONs) Sales Market Share by Region
8.2 North America
8.2.1 North America Oligonucleotide Drugs (ONs) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Oligonucleotide Drugs (ONs) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Oligonucleotide Drugs (ONs) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Oligonucleotide Drugs (ONs) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Oligonucleotide Drugs (ONs) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Novartis
9.1.1 Novartis Oligonucleotide Drugs (ONs) Basic Information
9.1.2 Novartis Oligonucleotide Drugs (ONs) Product Overview
9.1.3 Novartis Oligonucleotide Drugs (ONs) Product Market Performance
9.1.4 Novartis Business Overview
9.1.5 Novartis Oligonucleotide Drugs (ONs) SWOT Analysis
9.1.6 Novartis Recent Developments
9.2 Ionis
9.2.1 Ionis Oligonucleotide Drugs (ONs) Basic Information
9.2.2 Ionis Oligonucleotide Drugs (ONs) Product Overview
9.2.3 Ionis Oligonucleotide Drugs (ONs) Product Market Performance
9.2.4 Ionis Business Overview
9.2.5 Ionis Oligonucleotide Drugs (ONs) SWOT Analysis
9.2.6 Ionis Recent Developments
9.3 Nippon Shinyaku
9.3.1 Nippon Shinyaku Oligonucleotide Drugs (ONs) Basic Information
9.3.2 Nippon Shinyaku Oligonucleotide Drugs (ONs) Product Overview
9.3.3 Nippon Shinyaku Oligonucleotide Drugs (ONs) Product Market Performance
9.3.4 Nippon Shinyaku Oligonucleotide Drugs (ONs) SWOT Analysis
9.3.5 Nippon Shinyaku Business Overview
9.3.6 Nippon Shinyaku Recent Developments
9.4 Alnylam
9.4.1 Alnylam Oligonucleotide Drugs (ONs) Basic Information
9.4.2 Alnylam Oligonucleotide Drugs (ONs) Product Overview
9.4.3 Alnylam Oligonucleotide Drugs (ONs) Product Market Performance
9.4.4 Alnylam Business Overview
9.4.5 Alnylam Recent Developments
9.5 Sarepta Therapeutics
9.5.1 Sarepta Therapeutics Oligonucleotide Drugs (ONs) Basic Information
9.5.2 Sarepta Therapeutics Oligonucleotide Drugs (ONs) Product Overview
9.5.3 Sarepta Therapeutics Oligonucleotide Drugs (ONs) Product Market Performance
9.5.4 Sarepta Therapeutics Business Overview
9.5.5 Sarepta Therapeutics Recent Developments
9.6 MiNA Therapeutics
9.6.1 MiNA Therapeutics Oligonucleotide Drugs (ONs) Basic Information
9.6.2 MiNA Therapeutics Oligonucleotide Drugs (ONs) Product Overview
9.6.3 MiNA Therapeutics Oligonucleotide Drugs (ONs) Product Market Performance
9.6.4 MiNA Therapeutics Business Overview
9.6.5 MiNA Therapeutics Recent Developments
9.7 BioNTech
9.7.1 BioNTech Oligonucleotide Drugs (ONs) Basic Information
9.7.2 BioNTech Oligonucleotide Drugs (ONs) Product Overview
9.7.3 BioNTech Oligonucleotide Drugs (ONs) Product Market Performance
9.7.4 BioNTech Business Overview
9.7.5 BioNTech Recent Developments
9.8 Moderna
9.8.1 Moderna Oligonucleotide Drugs (ONs) Basic Information
9.8.2 Moderna Oligonucleotide Drugs (ONs) Product Overview
9.8.3 Moderna Oligonucleotide Drugs (ONs) Product Market Performance
9.8.4 Moderna Business Overview
9.8.5 Moderna Recent Developments
10 OLIGONUCLEOTIDE DRUGS (ONS) MARKET FORECAST BY REGION
10.1 Global Oligonucleotide Drugs (ONs) Market Size Forecast
10.2 Global Oligonucleotide Drugs (ONs) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Oligonucleotide Drugs (ONs) Market Size Forecast by Country
10.2.3 Asia Pacific Oligonucleotide Drugs (ONs) Market Size Forecast by Region
10.2.4 South America Oligonucleotide Drugs (ONs) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Oligonucleotide Drugs (ONs) by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Oligonucleotide Drugs (ONs) Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Oligonucleotide Drugs (ONs) by Type (2025-2030)
11.1.2 Global Oligonucleotide Drugs (ONs) Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Oligonucleotide Drugs (ONs) by Type (2025-2030)
11.2 Global Oligonucleotide Drugs (ONs) Market Forecast by Application (2025-2030)
11.2.1 Global Oligonucleotide Drugs (ONs) Sales (Kilotons) Forecast by Application
11.2.2 Global Oligonucleotide Drugs (ONs) Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Oligonucleotide Drugs (ONs) Market Size Comparison by Region (M USD)
Table 5. Global Oligonucleotide Drugs (ONs) Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Oligonucleotide Drugs (ONs) Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Oligonucleotide Drugs (ONs) Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Oligonucleotide Drugs (ONs) Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Drugs (ONs) as of 2022)
Table 10. Global Market Oligonucleotide Drugs (ONs) Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Oligonucleotide Drugs (ONs) Sales Sites and Area Served
Table 12. Manufacturers Oligonucleotide Drugs (ONs) Product Type
Table 13. Global Oligonucleotide Drugs (ONs) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Oligonucleotide Drugs (ONs)
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Oligonucleotide Drugs (ONs) Market Challenges
Table 22. Global Oligonucleotide Drugs (ONs) Sales by Type (Kilotons)
Table 23. Global Oligonucleotide Drugs (ONs) Market Size by Type (M USD)
Table 24. Global Oligonucleotide Drugs (ONs) Sales (Kilotons) by Type (2019-2024)
Table 25. Global Oligonucleotide Drugs (ONs) Sales Market Share by Type (2019-2024)
Table 26. Global Oligonucleotide Drugs (ONs) Market Size (M USD) by Type (2019-2024)
Table 27. Global Oligonucleotide Drugs (ONs) Market Size Share by Type (2019-2024)
Table 28. Global Oligonucleotide Drugs (ONs) Price (USD/Ton) by Type (2019-2024)
Table 29. Global Oligonucleotide Drugs (ONs) Sales (Kilotons) by Application
Table 30. Global Oligonucleotide Drugs (ONs) Market Size by Application
Table 31. Global Oligonucleotide Drugs (ONs) Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Oligonucleotide Drugs (ONs) Sales Market Share by Application (2019-2024)
Table 33. Global Oligonucleotide Drugs (ONs) Sales by Application (2019-2024) & (M USD)
Table 34. Global Oligonucleotide Drugs (ONs) Market Share by Application (2019-2024)
Table 35. Global Oligonucleotide Drugs (ONs) Sales Growth Rate by Application (2019-2024)
Table 36. Global Oligonucleotide Drugs (ONs) Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Oligonucleotide Drugs (ONs) Sales Market Share by Region (2019-2024)
Table 38. North America Oligonucleotide Drugs (ONs) Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Oligonucleotide Drugs (ONs) Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Oligonucleotide Drugs (ONs) Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Oligonucleotide Drugs (ONs) Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Oligonucleotide Drugs (ONs) Sales by Region (2019-2024) & (Kilotons)
Table 43. Novartis Oligonucleotide Drugs (ONs) Basic Information
Table 44. Novartis Oligonucleotide Drugs (ONs) Product Overview
Table 45. Novartis Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Novartis Business Overview
Table 47. Novartis Oligonucleotide Drugs (ONs) SWOT Analysis
Table 48. Novartis Recent Developments
Table 49. Ionis Oligonucleotide Drugs (ONs) Basic Information
Table 50. Ionis Oligonucleotide Drugs (ONs) Product Overview
Table 51. Ionis Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Ionis Business Overview
Table 53. Ionis Oligonucleotide Drugs (ONs) SWOT Analysis
Table 54. Ionis Recent Developments
Table 55. Nippon Shinyaku Oligonucleotide Drugs (ONs) Basic Information
Table 56. Nippon Shinyaku Oligonucleotide Drugs (ONs) Product Overview
Table 57. Nippon Shinyaku Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Nippon Shinyaku Oligonucleotide Drugs (ONs) SWOT Analysis
Table 59. Nippon Shinyaku Business Overview
Table 60. Nippon Shinyaku Recent Developments
Table 61. Alnylam Oligonucleotide Drugs (ONs) Basic Information
Table 62. Alnylam Oligonucleotide Drugs (ONs) Product Overview
Table 63. Alnylam Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Alnylam Business Overview
Table 65. Alnylam Recent Developments
Table 66. Sarepta Therapeutics Oligonucleotide Drugs (ONs) Basic Information
Table 67. Sarepta Therapeutics Oligonucleotide Drugs (ONs) Product Overview
Table 68. Sarepta Therapeutics Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Sarepta Therapeutics Business Overview
Table 70. Sarepta Therapeutics Recent Developments
Table 71. MiNA Therapeutics Oligonucleotide Drugs (ONs) Basic Information
Table 72. MiNA Therapeutics Oligonucleotide Drugs (ONs) Product Overview
Table 73. MiNA Therapeutics Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. MiNA Therapeutics Business Overview
Table 75. MiNA Therapeutics Recent Developments
Table 76. BioNTech Oligonucleotide Drugs (ONs) Basic Information
Table 77. BioNTech Oligonucleotide Drugs (ONs) Product Overview
Table 78. BioNTech Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. BioNTech Business Overview
Table 80. BioNTech Recent Developments
Table 81. Moderna Oligonucleotide Drugs (ONs) Basic Information
Table 82. Moderna Oligonucleotide Drugs (ONs) Product Overview
Table 83. Moderna Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Moderna Business Overview
Table 85. Moderna Recent Developments
Table 86. Global Oligonucleotide Drugs (ONs) Sales Forecast by Region (2025-2030) & (Kilotons)
Table 87. Global Oligonucleotide Drugs (ONs) Market Size Forecast by Region (2025-2030) & (M USD)
Table 88. North America Oligonucleotide Drugs (ONs) Sales Forecast by Country (2025-2030) & (Kilotons)
Table 89. North America Oligonucleotide Drugs (ONs) Market Size Forecast by Country (2025-2030) & (M USD)
Table 90. Europe Oligonucleotide Drugs (ONs) Sales Forecast by Country (2025-2030) & (Kilotons)
Table 91. Europe Oligonucleotide Drugs (ONs) Market Size Forecast by Country (2025-2030) & (M USD)
Table 92. Asia Pacific Oligonucleotide Drugs (ONs) Sales Forecast by Region (2025-2030) & (Kilotons)
Table 93. Asia Pacific Oligonucleotide Drugs (ONs) Market Size Forecast by Region (2025-2030) & (M USD)
Table 94. South America Oligonucleotide Drugs (ONs) Sales Forecast by Country (2025-2030) & (Kilotons)
Table 95. South America Oligonucleotide Drugs (ONs) Market Size Forecast by Country (2025-2030) & (M USD)
Table 96. Middle East and Africa Oligonucleotide Drugs (ONs) Consumption Forecast by Country (2025-2030) & (Units)
Table 97. Middle East and Africa Oligonucleotide Drugs (ONs) Market Size Forecast by Country (2025-2030) & (M USD)
Table 98. Global Oligonucleotide Drugs (ONs) Sales Forecast by Type (2025-2030) & (Kilotons)
Table 99. Global Oligonucleotide Drugs (ONs) Market Size Forecast by Type (2025-2030) & (M USD)
Table 100. Global Oligonucleotide Drugs (ONs) Price Forecast by Type (2025-2030) & (USD/Ton)
Table 101. Global Oligonucleotide Drugs (ONs) Sales (Kilotons) Forecast by Application (2025-2030)
Table 102. Global Oligonucleotide Drugs (ONs) Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Oligonucleotide Drugs (ONs) Market Size Comparison by Region (M USD)
Table 5. Global Oligonucleotide Drugs (ONs) Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Oligonucleotide Drugs (ONs) Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Oligonucleotide Drugs (ONs) Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Oligonucleotide Drugs (ONs) Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Drugs (ONs) as of 2022)
Table 10. Global Market Oligonucleotide Drugs (ONs) Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Oligonucleotide Drugs (ONs) Sales Sites and Area Served
Table 12. Manufacturers Oligonucleotide Drugs (ONs) Product Type
Table 13. Global Oligonucleotide Drugs (ONs) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Oligonucleotide Drugs (ONs)
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Oligonucleotide Drugs (ONs) Market Challenges
Table 22. Global Oligonucleotide Drugs (ONs) Sales by Type (Kilotons)
Table 23. Global Oligonucleotide Drugs (ONs) Market Size by Type (M USD)
Table 24. Global Oligonucleotide Drugs (ONs) Sales (Kilotons) by Type (2019-2024)
Table 25. Global Oligonucleotide Drugs (ONs) Sales Market Share by Type (2019-2024)
Table 26. Global Oligonucleotide Drugs (ONs) Market Size (M USD) by Type (2019-2024)
Table 27. Global Oligonucleotide Drugs (ONs) Market Size Share by Type (2019-2024)
Table 28. Global Oligonucleotide Drugs (ONs) Price (USD/Ton) by Type (2019-2024)
Table 29. Global Oligonucleotide Drugs (ONs) Sales (Kilotons) by Application
Table 30. Global Oligonucleotide Drugs (ONs) Market Size by Application
Table 31. Global Oligonucleotide Drugs (ONs) Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Oligonucleotide Drugs (ONs) Sales Market Share by Application (2019-2024)
Table 33. Global Oligonucleotide Drugs (ONs) Sales by Application (2019-2024) & (M USD)
Table 34. Global Oligonucleotide Drugs (ONs) Market Share by Application (2019-2024)
Table 35. Global Oligonucleotide Drugs (ONs) Sales Growth Rate by Application (2019-2024)
Table 36. Global Oligonucleotide Drugs (ONs) Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Oligonucleotide Drugs (ONs) Sales Market Share by Region (2019-2024)
Table 38. North America Oligonucleotide Drugs (ONs) Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Oligonucleotide Drugs (ONs) Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Oligonucleotide Drugs (ONs) Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Oligonucleotide Drugs (ONs) Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Oligonucleotide Drugs (ONs) Sales by Region (2019-2024) & (Kilotons)
Table 43. Novartis Oligonucleotide Drugs (ONs) Basic Information
Table 44. Novartis Oligonucleotide Drugs (ONs) Product Overview
Table 45. Novartis Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Novartis Business Overview
Table 47. Novartis Oligonucleotide Drugs (ONs) SWOT Analysis
Table 48. Novartis Recent Developments
Table 49. Ionis Oligonucleotide Drugs (ONs) Basic Information
Table 50. Ionis Oligonucleotide Drugs (ONs) Product Overview
Table 51. Ionis Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Ionis Business Overview
Table 53. Ionis Oligonucleotide Drugs (ONs) SWOT Analysis
Table 54. Ionis Recent Developments
Table 55. Nippon Shinyaku Oligonucleotide Drugs (ONs) Basic Information
Table 56. Nippon Shinyaku Oligonucleotide Drugs (ONs) Product Overview
Table 57. Nippon Shinyaku Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Nippon Shinyaku Oligonucleotide Drugs (ONs) SWOT Analysis
Table 59. Nippon Shinyaku Business Overview
Table 60. Nippon Shinyaku Recent Developments
Table 61. Alnylam Oligonucleotide Drugs (ONs) Basic Information
Table 62. Alnylam Oligonucleotide Drugs (ONs) Product Overview
Table 63. Alnylam Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Alnylam Business Overview
Table 65. Alnylam Recent Developments
Table 66. Sarepta Therapeutics Oligonucleotide Drugs (ONs) Basic Information
Table 67. Sarepta Therapeutics Oligonucleotide Drugs (ONs) Product Overview
Table 68. Sarepta Therapeutics Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Sarepta Therapeutics Business Overview
Table 70. Sarepta Therapeutics Recent Developments
Table 71. MiNA Therapeutics Oligonucleotide Drugs (ONs) Basic Information
Table 72. MiNA Therapeutics Oligonucleotide Drugs (ONs) Product Overview
Table 73. MiNA Therapeutics Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. MiNA Therapeutics Business Overview
Table 75. MiNA Therapeutics Recent Developments
Table 76. BioNTech Oligonucleotide Drugs (ONs) Basic Information
Table 77. BioNTech Oligonucleotide Drugs (ONs) Product Overview
Table 78. BioNTech Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. BioNTech Business Overview
Table 80. BioNTech Recent Developments
Table 81. Moderna Oligonucleotide Drugs (ONs) Basic Information
Table 82. Moderna Oligonucleotide Drugs (ONs) Product Overview
Table 83. Moderna Oligonucleotide Drugs (ONs) Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Moderna Business Overview
Table 85. Moderna Recent Developments
Table 86. Global Oligonucleotide Drugs (ONs) Sales Forecast by Region (2025-2030) & (Kilotons)
Table 87. Global Oligonucleotide Drugs (ONs) Market Size Forecast by Region (2025-2030) & (M USD)
Table 88. North America Oligonucleotide Drugs (ONs) Sales Forecast by Country (2025-2030) & (Kilotons)
Table 89. North America Oligonucleotide Drugs (ONs) Market Size Forecast by Country (2025-2030) & (M USD)
Table 90. Europe Oligonucleotide Drugs (ONs) Sales Forecast by Country (2025-2030) & (Kilotons)
Table 91. Europe Oligonucleotide Drugs (ONs) Market Size Forecast by Country (2025-2030) & (M USD)
Table 92. Asia Pacific Oligonucleotide Drugs (ONs) Sales Forecast by Region (2025-2030) & (Kilotons)
Table 93. Asia Pacific Oligonucleotide Drugs (ONs) Market Size Forecast by Region (2025-2030) & (M USD)
Table 94. South America Oligonucleotide Drugs (ONs) Sales Forecast by Country (2025-2030) & (Kilotons)
Table 95. South America Oligonucleotide Drugs (ONs) Market Size Forecast by Country (2025-2030) & (M USD)
Table 96. Middle East and Africa Oligonucleotide Drugs (ONs) Consumption Forecast by Country (2025-2030) & (Units)
Table 97. Middle East and Africa Oligonucleotide Drugs (ONs) Market Size Forecast by Country (2025-2030) & (M USD)
Table 98. Global Oligonucleotide Drugs (ONs) Sales Forecast by Type (2025-2030) & (Kilotons)
Table 99. Global Oligonucleotide Drugs (ONs) Market Size Forecast by Type (2025-2030) & (M USD)
Table 100. Global Oligonucleotide Drugs (ONs) Price Forecast by Type (2025-2030) & (USD/Ton)
Table 101. Global Oligonucleotide Drugs (ONs) Sales (Kilotons) Forecast by Application (2025-2030)
Table 102. Global Oligonucleotide Drugs (ONs) Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Oligonucleotide Drugs (ONs)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Oligonucleotide Drugs (ONs) Market Size (M USD), 2019-2030
Figure 5. Global Oligonucleotide Drugs (ONs) Market Size (M USD) (2019-2030)
Figure 6. Global Oligonucleotide Drugs (ONs) Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Oligonucleotide Drugs (ONs) Market Size by Country (M USD)
Figure 11. Oligonucleotide Drugs (ONs) Sales Share by Manufacturers in 2023
Figure 12. Global Oligonucleotide Drugs (ONs) Revenue Share by Manufacturers in 2023
Figure 13. Oligonucleotide Drugs (ONs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Oligonucleotide Drugs (ONs) Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Oligonucleotide Drugs (ONs) Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Oligonucleotide Drugs (ONs) Market Share by Type
Figure 18. Sales Market Share of Oligonucleotide Drugs (ONs) by Type (2019-2024)
Figure 19. Sales Market Share of Oligonucleotide Drugs (ONs) by Type in 2023
Figure 20. Market Size Share of Oligonucleotide Drugs (ONs) by Type (2019-2024)
Figure 21. Market Size Market Share of Oligonucleotide Drugs (ONs) by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Oligonucleotide Drugs (ONs) Market Share by Application
Figure 24. Global Oligonucleotide Drugs (ONs) Sales Market Share by Application (2019-2024)
Figure 25. Global Oligonucleotide Drugs (ONs) Sales Market Share by Application in 2023
Figure 26. Global Oligonucleotide Drugs (ONs) Market Share by Application (2019-2024)
Figure 27. Global Oligonucleotide Drugs (ONs) Market Share by Application in 2023
Figure 28. Global Oligonucleotide Drugs (ONs) Sales Growth Rate by Application (2019-2024)
Figure 29. Global Oligonucleotide Drugs (ONs) Sales Market Share by Region (2019-2024)
Figure 30. North America Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Oligonucleotide Drugs (ONs) Sales Market Share by Country in 2023
Figure 32. U.S. Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Oligonucleotide Drugs (ONs) Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Oligonucleotide Drugs (ONs) Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Oligonucleotide Drugs (ONs) Sales Market Share by Country in 2023
Figure 37. Germany Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Oligonucleotide Drugs (ONs) Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Oligonucleotide Drugs (ONs) Sales Market Share by Region in 2023
Figure 44. China Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Oligonucleotide Drugs (ONs) Sales and Growth Rate (Kilotons)
Figure 50. South America Oligonucleotide Drugs (ONs) Sales Market Share by Country in 2023
Figure 51. Brazil Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Oligonucleotide Drugs (ONs) Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Oligonucleotide Drugs (ONs) Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Oligonucleotide Drugs (ONs) Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Oligonucleotide Drugs (ONs) Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Oligonucleotide Drugs (ONs) Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Oligonucleotide Drugs (ONs) Market Share Forecast by Type (2025-2030)
Figure 65. Global Oligonucleotide Drugs (ONs) Sales Forecast by Application (2025-2030)
Figure 66. Global Oligonucleotide Drugs (ONs) Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Oligonucleotide Drugs (ONs)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Oligonucleotide Drugs (ONs) Market Size (M USD), 2019-2030
Figure 5. Global Oligonucleotide Drugs (ONs) Market Size (M USD) (2019-2030)
Figure 6. Global Oligonucleotide Drugs (ONs) Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Oligonucleotide Drugs (ONs) Market Size by Country (M USD)
Figure 11. Oligonucleotide Drugs (ONs) Sales Share by Manufacturers in 2023
Figure 12. Global Oligonucleotide Drugs (ONs) Revenue Share by Manufacturers in 2023
Figure 13. Oligonucleotide Drugs (ONs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Oligonucleotide Drugs (ONs) Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Oligonucleotide Drugs (ONs) Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Oligonucleotide Drugs (ONs) Market Share by Type
Figure 18. Sales Market Share of Oligonucleotide Drugs (ONs) by Type (2019-2024)
Figure 19. Sales Market Share of Oligonucleotide Drugs (ONs) by Type in 2023
Figure 20. Market Size Share of Oligonucleotide Drugs (ONs) by Type (2019-2024)
Figure 21. Market Size Market Share of Oligonucleotide Drugs (ONs) by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Oligonucleotide Drugs (ONs) Market Share by Application
Figure 24. Global Oligonucleotide Drugs (ONs) Sales Market Share by Application (2019-2024)
Figure 25. Global Oligonucleotide Drugs (ONs) Sales Market Share by Application in 2023
Figure 26. Global Oligonucleotide Drugs (ONs) Market Share by Application (2019-2024)
Figure 27. Global Oligonucleotide Drugs (ONs) Market Share by Application in 2023
Figure 28. Global Oligonucleotide Drugs (ONs) Sales Growth Rate by Application (2019-2024)
Figure 29. Global Oligonucleotide Drugs (ONs) Sales Market Share by Region (2019-2024)
Figure 30. North America Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Oligonucleotide Drugs (ONs) Sales Market Share by Country in 2023
Figure 32. U.S. Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Oligonucleotide Drugs (ONs) Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Oligonucleotide Drugs (ONs) Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Oligonucleotide Drugs (ONs) Sales Market Share by Country in 2023
Figure 37. Germany Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Oligonucleotide Drugs (ONs) Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Oligonucleotide Drugs (ONs) Sales Market Share by Region in 2023
Figure 44. China Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Oligonucleotide Drugs (ONs) Sales and Growth Rate (Kilotons)
Figure 50. South America Oligonucleotide Drugs (ONs) Sales Market Share by Country in 2023
Figure 51. Brazil Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Oligonucleotide Drugs (ONs) Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Oligonucleotide Drugs (ONs) Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Oligonucleotide Drugs (ONs) Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Oligonucleotide Drugs (ONs) Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Oligonucleotide Drugs (ONs) Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Oligonucleotide Drugs (ONs) Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Oligonucleotide Drugs (ONs) Market Share Forecast by Type (2025-2030)
Figure 65. Global Oligonucleotide Drugs (ONs) Sales Forecast by Application (2025-2030)
Figure 66. Global Oligonucleotide Drugs (ONs) Market Share Forecast by Application (2025-2030)